Smart SELECTA Duet

Your Smart Selection for Glaucoma Care





0

0.3

www.lumenis.com/Ophthalmology

20 Years of SLT Innovation

Lumenis, the world's pioneer of SLT technology, celebrates 20 years of SLT innovation by launching the newest anterior segment laser platform, the Smart Selecta Duet. Smart Selecta Duet encapsulates Lumenis' reliable core, offering cutting edge design, enhanced optics, and a superior panel PC with adjustable display.

UBRATING 20 Smart Selecta Duet combines the advantages of Selective Laser Trabeculoplasty (SLT) with the capacity of YAG photodisruption, while also allowing titratable vitreous PRS opacities' illumination (on-axis and off-axis). SLT INNOVA Cutting edge design Extremenly low optical Smart-V: anterior breakdown and posterior vitreous opacities' illumination Lumenis' SLT & YAG Panel PC inside, allowing with adjustable on-axis and off-axis 12" touch screen illumination and treatment Wheelchair accessible table 610 with convenient CA C 1940 control features Л л (Lumenia 0 -3)




Smart Selecta Duet is now available with the Smart-V upgrade:

Vitreous Opacities

- V Titratable illumination of both anterior and posterior Vitreous Opacities
- V SLT can be treated with on-axis illumination, as well as off-axis if needed
- V Less red reflex: two converging light beams that allow superior visibility of the vitreous
- V Effective Capsulotomy and Iridotomy at lower and more efficient power levels
- V Stable solution that enables the visualization of the treatment area at all times (no flickering)
- \vee Easily upgradable at any time with the Smart Selecta Duet





Stable Reliable Upgradable

The Smart Choice for Your Clinic

Effective Treatment

Lumenis SLT is clinically proven as first line therapy for glaucoma. 1, 2

Hundreds of studies have demonstrated the effectiveness of Lumenis SLT for open angle glaucoma, with over 80% success rate for reducing IOP. 3, 4

Signature Laser Design with Proprietary Advantages

The Smart Selecta Duet is the next generation of ophthalmic lasers, empowering doctors with numerous proprietary features:

- Automatic internal testing, ensuring power requirements
- Secondary control unit, guaranteeing power precision
- Unique temperature-controlled KTP crystal, guaranteeing laser beam stability and accuracy

Uncompromised Quality & Service

- Lumenis SLT systems are proudly manufactured in the USA
- Lumenis delivers fast service, with more than 50 direct field service engineers committed to a rapid on-site response.

Super Gaussian Beam Profile in YAG Mode

Smart Selecta Duet features a highly accurate Super Gaussian beam profile, for achieving optical breakdown (or photo disruption) with minimized energy levels.

1. McIlraith I, Strasfeld M, Colev G, Hutnik CML. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006; 15:124-1304 Damji KF, Bovell AM, Hodge WG.

2. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. Arch Ophthalmol. 2003; 121:957-960.

3. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Opthalmology. 2004; 111:1853-1859.

4. Damji KF, Bovell AM, Hodge WG. Selective laser trabeculoplasty: a review and comparison to argon laser trabeculoplasty. Ophthalmic Pract. 2003; 21:54-58.

The Smart Choice for Your Patient



The Smart Selecta Duet offers patients a safe and effective treatment. Lumenis SLT core technology puts into practice two decades of professional research and industry experience, clinically proven for the treatment of open angle glaucoma, backed by hundreds of studies. System safety measures and a built-in energy indicator ensure accurate energy delivery throughout every treatment. Smart Selecta Duet is the SLT of choice of leading ophthalmic institutions across the USA.

Every Clinic Needs Its Lumenis SLT

Innovation is advancing at unprecedented speed, and so are the efforts to find the gold standard protocol for glaucoma care. One thing remains unchanged over the past 20 years – every clinic has numerous patients who depend on SLT treatments to secure their ocular health.

"We use SLT as first line therapy in just about every patient that comes in, and who's a good patient, so we offer SLT as primary therapy and I think this is probably the most important role that SLT has played in the management of Glaucoma."

Mark A. Latina, MD⁵

"Studies show that SLT is an effective primary therapy in appropriate patients, working as well as drops without the compliance issues or side effects such as ocular hyperemia and ocular surface disease." Nathan M. Radcliffe, MD^{6,7}

Every clinic needs its SLT, we offer you the smartest. Smart Selecta Duet.

6. Waisbourd M, Katz LJ. Selective laser trabeculoplasty as a first-line therapy: a review. Can J Ophthalmol. 2014 Dec; 49:519-522.

^{5.} SLT Physician Testimonials Mark A. Latina, MD for the AAO 2013.


^{7.} Katz LJ, Steinmann WC, Kabir A, et al; SLT/Med Study Group. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012 Sep; 21:460-468.

Lumenis SLT

The Preferred Choice of Leading Ophthalmic Institutions in the USA

- Bascom Palmer Eye Institute-Anne Bates Leach
- Eye Hospital, FL
- Wills Eye Hospital, PA
- Wilmer Eye Institute, Johns Hopkins Hospital, MD
- Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, MA
- Stein and Doheny Eye Institutes, UCLA Medical Center, CA
- Duke University Hospital, NC
- Cleveland Clinic, OH
- University of Iowa Hospitals and Clinics, IA
- USC Eye Institute-Keck Medical Center of USC, CA
- New York Eye and Ear Infirmary, NY
- W.K. Kellogg Eye Center, University of Michigan, MI
- Cullen Eye Institute-Baylor, Methodist Hospital, TX
- Dean McGee Eye Institute, OU Medical Center, OK
- Emory University Hospital, GA
- Hospitals of the University of Pennsylvania-Penn
 Presbyterian, PA

- Kresge Eye Institute, MI
- Lenox Hill Hospital-Manhattan Eye, Ear and Throat Institute, NY
- Mayo Clinic, MN
- Medical University of South Carolina, SC
- New York-Presbyterian University Hospital of Columbia and Cornell, NY
- Northwestern Memorial Hospital, IL
- Oregon Health and Science University Hospital, OR
- Stanford Hospital and Clinics, CA
- Tufts Medical Center Boston, MA
- UC San Diego Medical Center, CA
- UCSF Medical Center, CA
- University of Chicago Medical Center, IL
- University of Illinois Hospital, Chicago, IL
- University of Miami Hospital, FL



Smart ECTA Specifications

	YAG Photodisruptor Mode	SLT Mode
Laser Source	Q-Switched Nd:YAG	Q-Switched, frequency doubled Nd:YAG
Wavelength	1064 nm	532 nm
Energy (power)	0.3 - 10 mJ per pulse	0.3 - 2.0 mJ per pulse, continuously variable in 0.1 mJ increments
Pulse Duration	3 ns	3 ns
Burst Mode	1, 2, or 3 pulses per burst (selectable)	Single pulse
Spot Size	8 µm	400 µm
Cone Angle	16 degrees	< 3 degrees
Posterior Offset	0 - 350 µm (continuously variable)	Not applicable
Repetition rate	3 Hz (in single burst)	3 Hz
Aiming Beam	Red diode, continuously variable with adjustable intensity	Red diode, continuously variable with adjustable intensity
Cooling	Air Cooled	Air Cooled
Electrical Requirements	100 -240 VAC, 50/60 Hz, 3.15 Amps	100 -240 VAC, 50/60 Hz, 3.15 Amps
CDRH Classification	FDA IIIb	FDA IIIb
Smart Selecta Duet Table	Table height Wheelchair accessible, 945 mm max, 695 mm min, travel ~250 mm (37.8 in max, 27.4 in min, travel ~10.4 in) Table width Small: 630 mm (24.8 in) Medium: 880 mm (34.5 in), Table depth Small: 400 mm (15.7 in) Medium: 450 mm (17.8 in), Table wheel base Small: 520 mm x 440 mm (20.4 in x 17.2 in), Medium: 460 mm x 830 mm (18.1 in x 32.7 in), Total system weight <60 kg	

Risks and warnings: Smart Selecta Duet is intended solely for use by trained physicians. SLT: contraindicated for eyes with neovascular or angle-closure glaucoma. Risks include iritis, conjunctivitis and IOP rise. YAG: contraindicated for eyes with corneal pathologies and chronically elevated IOP. Risks include IOP rise, macular edema and retinal detachment. Refer to the operator manual for a complete list of intended use, contraindications and risks.

Lumenis® Certified Service | USA Toll-free 1-877-LUMENIS (1-877-586-3647)

Lumenis Inc. Eumenis (Germany) GmbH AMERICAS **EMEA** JAPAN ASIA / PACIFIC 1870 South Milestone Drive Heinrich-Hertz-Str 3 D-63303 San Jose, CA, USA Dreieich Dreieichenhain, Tokyo, Japan Beijing, China Salt Lake City, UT 84104 USA Dreieich-Dreieichenhain Tel +81 3 4431 8300 Tel +1 408 764 3000 Tel +86 10 5737 6677 Germany GERMANY Tel +801-656-2300 +1 877 586 3647 Tel +49 6103 8335 0 Fax +81 3 4431 8301 Gurgaon, India Tel +49 (0) 6103 8335 0 Fax +801-656-2429 Fax +1 408 764 3999 Fax +49 6103 8335 300 Tel +91 124 422 07 95 Roma (RM), Italy Kowloon, Hong Kong Tel +39 06 90 75 230 Tel +852 217 428 00 Fax +39 06 90 75 269 VISIBLE AND INVISIBLE LASER RADIATION AVOID EXPOSURE TO BEAM CLASS 3B LASER PRODUCT NGYAG: 320 m, 10 mJ Max / 3 ns pulse Fax +852 272 251 51 **RX Only** Hertfordshire, UK Tel +44 20 8736 4110 Fax +44 20 8736 4119 VISIBLE LASER RADIATION DO NOT STARE INTO BEAM CLASS 2 LASER PRODUCT Diode Laser: 635 nm, <1 mW Max, CW 1014 10 & 1040.11 ISO 13485 CERTIFIED umenis

Energy to Healthcare

www.lumenis.com/Ophthalmology

© 2018 All Rights Reserved. The Lumenis Group of Companies. PB-2005807 Rev. D